
Please try another search
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Birgitte Volck | 63 | 2019 | Independent Director |
William G. Harris | 67 | 2014 | Independent Director |
Shamim Ruff | 65 | 2024 | Chair of the Development Advisory Board |
James Arthur Geraghty | 71 | 2024 | Member of Advisory Board |
Thomas B. Casale | - | - | Member of Advisory Board |
Anish Bhatnagar | 55 | 2013 | Chairman, President, CEO & COO |
Glenis Kathleen Scadding | - | - | Member of Advisory Board |
Vinod K. Bhutani | - | - | Member of Advisory Board |
Andrew Sinclair | 53 | 2018 | Independent Director |
Robert D. Christensen | - | - | Member of Advisory Board |
David K. Stevenson | - | - | Member of Advisory Board |
Matthew Pauls | 54 | 2023 | Lead Independent Director |
Dawn Carter Bir | 54 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review